In patients with impaired motor function or receiving antipsychotic drugs are rarely informed enanthate testosterone about the development of extrapyramidal symptoms, including oro-facial dystonia.
Violations of the organs of vision Frequent: . Blurred vision Uncommon: mydriasisVery rare: acute glaucoma. Violations of the heart: Uncommon: sinus tachycardia Vascular disorders Uncommon: postural hypotension violations by respiratory, thoracic and mediastinal disorders Common:yawning. gastrointestinal disorders Very common: nausea. Common: constipation, diarrhea, vomiting, dry mouth. Very rare: gastrointestinal bleeding. Hepatobiliary disorders rare: . increased liver enzymesVery rare: hepatitis, sometimes accompanied by jaundice and / or liver failure. Sometimes there is increased levels of liver enzymes. Post-marketing reports of liver damage (such as hepatitis, sometimes. With jaundice and / or liver failure) are very rare.
The question of the appropriateness of discontinuation of treatment with paroxetine should be addressed in cases where there is prolonged elevation of indices of liver function tests. Violations of the skin and subcutaneous tissue Frequent: . Sweating Uncommon: . Skin rashes Very rare: photosensitivity reactions. Violations of the kidney and urinary tract Rare: . urinary retention, urinary incontinence Disorders reproductive system and breast Very common: sexual General Common: fatigue, weight gain. Very rare: peripheral edema. The symptoms arising from the termination of treatment with paroxetine: Common: dizziness, sensory disturbances, sleep disturbances, anxiety, headache. Uncommon: agitation, nausea, tremor, confusion, sweating, diarrhea:
As with the abolition of many psychoactive medicines, discontinuation of treatment with paroxetine (particularly sharp) can cause symptoms such as dizziness, sensory disturbances (including paraesthesia, feeling an electric shock and tinnitus), sleep disturbances (including intense dreams), agitation or anxiety, nausea, headache, tremor, confusion, diarrhea and sweating. In most patients, these symptoms are mild to moderate and go spontaneously. It is not known any one group of patients who would be at increased risk of these symptoms; if so. in the treatment of paroxetine enanthate testosterone is no longer necessary, the dose should be reduced slowly until the full withdrawal of the drug.
Adverse events observed in clinical trials in children
in clinical trials in children following side effects occurred in 2% of patients and occurred in the paroxetine group were twice as likely, than in the placebo group:. emotional lability (including self-harm, suicidal thoughts, suicide attempts, crying and mood fluctuations), hostility, decreased appetite, tremor, sweating, hyperkinesia and agitation
suicidal thoughts and suicide attempts were mainly observed in clinical trials in adolescents with major depressive disorder, in which the efficacy of paroxetine has not been proved. Hostility was observed in children with obsessive-compulsive disorder, especially in children younger than 12 years.
Withdrawal symptoms paroxetine (emotional lability, nervousness, dizziness, nausea and abdominal pain) were recorded in 2% of patients on the background of reducing the dose of paroxetine or after its complete abolition and met 2 times more often than in the placebo group.
objective and subjective symptoms of
available information on overdose of paroxetine shows its wide range of safety. In case of overdose of paroxetine in addition to the symptoms described in the section “Side effects” are observed fever, blood pressure changes, involuntary muscle contractions, anxiety and tachycardia.
Patients were usually returned to normal without serious consequences even for the occasional admission doses up to 2000 mg. A number of reports described symptoms such as coma and ECG changes.deaths were very rare, usually in situations where patients received paroxetine together with other psychotropic medications or with alcohol.
specific antidote paroxetine exists. Treatment should consist of the general measures used in any overdose of antidepressants. It is shown that maintenance treatment and frequent monitoring of vital signs.Treatment of the patient should be in accordance with the clinical picture, or in accordance with the national poison center’s recommendations.
Important information Children enanthate testosterone and adolescents (under 18 years) antidepressant treatment of children and adolescents, tradayuschih major depressive disorder and other mental illnesses, is associated with an increased risk of suicidal thoughts or suicidal behavior. In clinical studies, adverse events associated with suicide attempts and suicidal thoughts and hostility (predominantly aggression, deviant behavior and anger) were more frequently observed in children and adolescents treated with paroxetine compared with patients in this age group who received placebo. There is currently no data on the long-term safety of paroxetine for children and adolescents, which related to the impact of the drug on the growth, maturation, cognitive and behavioral development. Clinical worsening and suicide risk in adults Young patients, especially those with major depressive disorder may be at increased risk of suicidal behavior during treatment with paroxetine. The analysis of placebo-controlled studies in adults with mental illness, indicates an increase in the frequency of suicidal behavior in young adults (aged 18-24 years) in patients receiving paroxetine compared with placebo (2.19% to 0.92% respectively ), although this difference is not considered statistically significant. Patients older age groups (25 to 64 years and 65 years) to increase the frequency of suicidal behavior in the observed. Adults of all ages suffering from major depressive disorder, a statistically significant increase in the incidence of suicidal behavior during treatment with paroxetine compared with placebo (incidence of suicide attempts: 0.32% to 0.05%, respectively). However, most of these cases, in patients receiving paroxetine (8 of 11) have been reported in young patients between the ages of 18-30 years.
Data from the study in patients with major depressive disorder may indicate an increase in the frequency of suicidal behavior in patients younger than 24 years old, suffering from various mental disorders. Patients with symptoms of depression, exacerbation of the disorder, and / or the appearance and suicidal thoughts of suicide (suicidality) can be observed regardless of whether they receive antidepressants.
This risk persists until such time until you reach the marked remission. Improving the condition of the patient may not be available in the first weeks of treatment and more, and therefore the patient should be closely observed for early detection of clinical worsening and suicidality, especially at the beginning of treatment, as well as during periods of changing doses, whether they increase or decrease. Clinical experience with all antidepressants shows that the risk of suicide may increase in the early stages of recovery. Other psychiatric disorders, which are used for the treatment of paroxetine may also be associated with increased risk of suicidal behavior. In addition, these disorders can be comorbid conditions, concomitant major depressive disorder. Therefore, the treatment of patients suffering from other mental disorders, should comply with the same precautions as in the treatment of major depressive disorder. The greatest risk of suicidal thoughts or suicide attempts are exposed to patients with a history of suicidal enanthate testosterone behavior or suicidal thoughts, patients are younger, and patients with severe suicidal thoughts prior to treatment, and, therefore, all of them need special attention during treatment.
Patients (and those caring for them) to warn of the need to monitor the deterioration of their condition and / or the emergence of suicidal ideation / suicidal behavior or thoughts of hurting yourself during the course of treatment, especially at the beginning of treatment, when changing the dose (increase and decrease). oxydrolone